Skip to content
DataLookout
Menu

NCT03190915

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 221 versions: 14 with changes below, 36 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Collaborators expanded, about 3 words
  2. Minor Collaborators shortened, about 3 words
  3. Notable Eligibility criteria shortened, about 1 word Show 5 more changesShow less
    • Study completion pushed from Oct 3, 2026 to Oct 14, 2027
    • Secondary endpoints: details revised at 5 of 6 entries
    • Site details revised at 40 of 57 sites
    • Collaborators: details revised at 1 of 1 entry
    • Publications: details revised at 2 of 2 entries
  4. Minor Study sites revised (57)v216
  5. Minor Study completion date: Oct 3, 2025 to Oct 3, 2026v187
Show 9 earlier versionsHide 9 earlier versions
  1. Minor Study completion date: Sep 22, 2024 to Oct 3, 2025v184
  2. Minor Study sites revised (57)v183
  3. Notable Results first posted: Jul 16, 2024
    • Secondary endpoints: details revised at 1 of 6 entries
    v181
  4. Minor Secondary endpoints: details revised at 1 of 6 entriesv180
  5. Minor Secondary endpoints revised (6)
    • Primary endpoint revised
    v179
  6. Minor Secondary endpoints: details revised at 4 of 6 entriesv177
  7. Notable Start date: Oct 6, 2017 to Sep 9, 2018
    • Study completion date: May 8, 2024 to Sep 22, 2024
    v176
  8. Minor Interventions: Bone Marrow Aspiration and Biopsy (Procedure), Computed Tomography (Procedure), Magnetic Resonance Imaging (Procedure), Trametinib (Drug) to Bone Marrow Aspiration and Biopsy (Procedure), Trametinib (Drug)
    • Secondary endpoints: 2 to 6
    • Study description shortened, about 13 words
    v174
  9. Minor Enrollment target: estimated 24 to confirmed 10
    • Primary completion date changed from estimate of Mar 31, 2027 to Mar 31, 2023
    • Study completion date: Mar 31, 2027 to May 8, 2024
    v173
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Objective Response
Timeframe: 12 cycles (1 cycle = 28 days)

Secondary (6)

Incidence of Adverse Events
Pharmacokinetic (PK) Parameters of Trametinib
Trametinib Concentrations
Mutant Allele Burden
Complete Response
Show 1 moreShow less
Duration of Response

Arms and interventions

Treatment (trametinib)Experimental

Patients receive trametinib PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo a bone marrow aspiration or biopsy at baseline, on day 28 of cycles 1 and 2, at all subsequent odd numbered cycles, and at end of treatment.

Procedures: Bone Marrow Aspiration and Biopsy

Drugs: Trametinib

Sites

57 sites in 1 country